People: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

12:41am IST
Change (% chg)

$-4.16 (-2.77%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Stoffels, Paulus 

Dr. Paulus A. Stoffels is the Vice Chairman- Executive Committee, Chief Scientific Officer of the Company. Dr. Stoffels joined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company's therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was appointed Chief Scientific Officer, with responsibility for enterprise-wide innovation and product safety, and became a member of the Executive Committee. In April 2016, Dr. Stoffels was named Executive Vice President, Chief Scientific Officer. He is responsible for the Company’s innovation pipeline across the pharmaceutical, medical devices and consumer segments and steers the Company’s global public health strategy.

Basic Compensation

Total Annual Compensation, USD 3,369,900
Restricted Stock Award, USD 4,666,960
Long-Term Incentive Plans, USD --
All Other, USD 2,554,900
Fiscal Year Total, USD 10,591,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 102,692 6,445,980.00
Name Fiscal Year Total

Alex Gorsky


Paulus Stoffels


Joaquin Duato


Joseph Wolk


Peter Fasolo


Michael Ullmann

As Of  31 Dec 2018